ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.
 PMID: 25061278       2014       Drug design, development and therapy
Abstract: Amino acid substitutions of rtL180M, rtS202G, and rtM204V emerged and were associated with an increase in serum HBV DNA at virologic breakthrough.
Abstract: At the start of combination therapy, amino acid substitutions of the reverse transcriptase (rt) gene, rtL180M, rtT184I/M, and rtM204V, were detected.
Conclusion: In comparison with those at the start of TDF therapy, the amino acid substitutions changed from rt


  Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
 PMID: 25028473       2014       The Journal of general virology
Abstract: Replication-competent HBV constructs containing rtI187V and combined with LAM-resistant (rtM204I, rtL180M/rtM204V) mutations were generated, and compared with WT, LAM-resistant single (rtM204I) or double (rtL180M/rtM204V) and ADV-resistant (rtN236T) clones.


  Clinical and virological characteristics associated with severe acute hepatitis B.
 PMID: 24930916       2014       Clinical microbiology and infection
Abstract: The 19 patients with severe or fulminant AVH-B more frequently than the 119 with a normal course stated intravenous drug use (63.2% versus 36.1%, p 0.04) and were HBV-DNA negative (31.6% versus 11.8%, p 0.03) and anti-hepatitis C virus (HCV) positive (57.9% versus 19.3%, p 0.0008); the prevalences of different HBV genotypes and of the rtM204V/I mutant were similar in these three forms of AVH-B.
Abstract: The HBV mutants in the polymerase region were sought in 110 (87%) patients by direct sequencing, and the rtM204V/I mutations also by an allele-specific PCR.


  Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.
 PMID: 24915064       2014       PloS one
Abstract: Among 9 patients on antiretroviral treatment (ART), one patient had the [L180M, M204V] mutation associated with lamivudine resistance.
Result: Among 9 patients on ART, one patient had the [L180M, M204V] mutations conferring resistance to lamivudine.
Table: M204V


  Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
 PMID: 24861361       2014       Journal of medical virology
Abstract: Allele-specific PCR assays capable of detecting rtM204V or rtM204I subpopulations as low as 0.5% were developed and used to assess patient samples from a Phase 3b study evaluating TDF and FTC/TDF treatment in LAM-R patients.
Abstract: Baseline samples (n = 280) were quantified for rtM204V/I subpopulations and rtM204V or rtM204I subpopulations were detected in 269/273 (98.5%) baseline samples with a range of 0.7% to >95%.
Abstract: In conclusion, rtM204V/I subpopulations demonstrate similar early HBV DNA decline kinetics to WT subpopulations


  Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy.
 PMID: 24836314       2014       Journal of clinical virology
Abstract: A 54-year-old man diagnosed with HBeAg-positive chronic hepatitis B (CHB) was treated with entecavir (ETV) 1mg/day following an initial unsuccessful lamivudine (LAM) treatment (rtL180M, rtM204V/I).
Abstract: However, this patient experienced virological breakthrough under TDF with a HBV strain bearing rtL80M, rtL180M, rtM204V/I, rtA200V, rtF221Y, rt PMID: 24835494       2014       PloS one
Abstract: Especially the lamivudine resistance mutations rtL180M/rtM20
Discussion: Besides other previously described resistance mutations, the best-described drug resistance mutations are the LAM resistance mutations rtL180M and rtM204V/I and the adefovir resistance mutations rtA181V/T and rtN236T.
Discussion: The LAM mutations rtM204V/I are mapped to the catalytic center of the viral RT domain, the YMDD motif.


  Analysis of reverse transcriptase gene mutations in the hepatitis B virus at a university hospital in Korea.
 PMID: 24790911       2014       Annals of laboratory medicine
Result: The rtM204I/V mutation (50.2%) was most frequently detected, followed by rtL180M (39.2%) and rtA181V/T (19.6%) mutations.
Result: There was no statistical difference of HBeAg positive rates among rtM204V, rtL180M, and rtM204I mutant groups.
Result: When the rtM204V and rtM204I mutation groups were compared, all 72 cases of rt


  Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.
 PMID: 24788140       2014       PloS one
Introduction: For example, resistance to lamivudine and telbivudine is conferred by mutation rtM204V or rtM204I in the YMDD motif, and this is often associated with compensatory mutations rtL180M and/or rtV173L restoring a higher replication capacity.
Result: It is worth noting that we did not observe any of the common NA-related resistance mutations including rtM204V/I, rtS202C/G/I, rtL180M, rt
 PMID: 24697270       2014       The Journal of organic chemistry
Abstract: FMCA demonstrated excellent anti-HBV activity against both adefovir-resistant and lamivudine-resistant double (rtL180M/rtM204V) mutants as well as in lamivudine/entecavir triple mutants (L180M+S202G+M204V) in vitro.



Browser Board

 Co-occurred Entities




   Filtrator